Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.
Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.
Eligibility criteria
Qualifiers
All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.
Absence of significant epicardial coronary artery disease on angiography
Fractional flow reserve > 0.80
Epicardial coronary spasm on acetylcholine testing
Disqualifiers
Acute coronary syndrome less than one week prior to enrolment
Cardiomyopathy
Contraindications to beta-blockers or calcium channel blockers
Baseline systolic blood pressure < 95 mmHg
Trial design
Treatments tested in this trial
- Amlodipine
- Nebivolol
- Placebo
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
American Heart Association
Collaborator
Source ClinicalTrials.gov